PTPRC and neoplasm: EPCs are further segregated into CD45+ and CD45− subsets; the CD45+ EPCs, marking an earlier erythroid differentiation stage, comprise over 40% of the EPC population in tumor-bearing mice and are chiefly accountable for immunosuppression [169, 171].